Tirzepatide is more effective than semaglutide for weight loss, according to a new study on GLP-1 medications ; The study was ...

The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...

Tirzepatide, a weekly GLP-1 and GIP drug sold under the brand name Zepbound, produced weight loss of up to 17.8% after 72 weeks, the analysis found. REUTERS McGill researchers are calling for more ...

Tirzepatide is sold under the name Mounjaro for diabetes. Semaglutide, when marketed for weight loss, is sold at a higher dose and called Wegovy; at a lower dose, it’s marketed for diabetes and ...

The drug, called Mounjaro for diabetes, will be called Zepbound for weight loss, according to a news release from the FDA. Made by Eli Lilly, it’s part of a new class of drugs that includes ...

In 2021, the US Food and Drug Administration approved semaglutide for people who are obese without diabetes who only need to lose weight. It’s sold under the brand name Ozempic when prescribed ...